{"_id": "64ffe48f748b29c10bbbeaec", "nctId": "NCT03426891", "title": "A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma", "Not yet fixed MQL": "{\n\"and\": [\n{\n\"$and\": [\n{\"diagnosis\": {\"$in\": [\"glioblastoma\", \"gliosarcoma\"]}},\n{\"histological diagnosis\": \"World Health Organization Grade IV malignant glioma\"}\n]\n},\n{\"days since surgical resection prior to treatment on the trial\": {\"$gte\": 21}},\n{\"Karnofsky performance status\": {\"$gte\": 70}},\n{\"adequate organ function laboratory values\": true},\n{\"resting baseline O2 saturation by pulse oximetry\": {\"$gte\": 92}},\n{\"able to provide written informed consent/assent for the trial\": true},\n{\"life expectancy\": {\"$gte\": 84}},\n{\n\"$and\": [\n{\"willingness to discontinue medications known to be associated with risk of Torsades de Pointes\": true},\n{\"such as\": {\"$in\": [\"quinidine\", \"procainamide\", \"disopyramide\", \"amiodarone\", \"erythromycin\", \"clarithromycin\", \"chlorpromazine\", \"haloperidol\"]}}\n]\n},\n{\"single lesion < 4 cm in longest diameter (diameter of enhancing lesion)\": true},\n{\"prior anti-cancer therapy for glioblastoma\": false},\n{\n\"$and\": [\n{\"females of childbearing potential (FOCBP) negative pregnancy test\": {\"$in\": [\"urine\", \"serum\"]}},\n{\n\"$or\": [\n{\"urine test is positive\": true},\n{\"cannot be confirmed as negative\": true}\n]\n}\n]\n},\n{\n\"$and\": [\n{\"females and males of childbearing potential must be willing to use an adequate method of contraception per protocol for the course of the study through 120 days after the last dose of study medication\": true},\n{\"abstinence is acceptable if this is the usual lifestyle and preferred contraception for participant\": true}\n]\n},\n{\"use of Optune device is allowed\": true},\n{\n\"$not\": {\n\"$or\": [\n{\"prior treatment of glioblastoma (GBM) with radiation and temozolomide\": true},\n{\"evidence of leptomeningeal disease\": true},\n{\"prior treatment with Gliadel\": true},\n{\"unable (due to existent medical condition) or unwilling to have a contrast enhanced MRI of brain\": true},\n{\"currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\": true},\n{\n\"$and\": [\n{\"diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\": true},\n{\"physiologic doses of steroid therapy (\u2264 2 mg/day dexamethasone equivalents) by the time of first dose of treatment are allowed\": true}\n]\n},\n{\"known history of active Bacillus Tuberculosis (TB)\": true},\n{\"hypersensitivity to pembrolizumab or any of its excipients\": true},\n{\n\"$and\": [\n{\"prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\": true},\n{\"prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent\": true}\n]\n},\n{\n\"$and\": [\n{\"known additional malignancy that is progressing or requires active treatment\": true},\n{\n\"$not\": {\n\"$or\": [\n{\"basal cell carcinoma of the skin that has undergone potentially curative therapy\": true},\n{\"squamous cell carcinoma of the skin that has undergone potentially curative therapy\": true},\n{\"in situ cervical cancer\": true}\n]\n}\n}\n]\n},\n{\n\"$and\": [\n{\"active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)\": true},\n{\n\"$not\": {\n\"$or\": [\n{\"replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.)\": true},\n{\"patients with vitiligo or resolved childhood asthma/atopy\": true},\n{\"patients that require intermittent use of bronchodilators or local steroid injections\": true},\n{\"patients with hypothyroidism stable on hormone replacement\": true},\n{\"patients with Sjorgen's syndrome\": true}\n]\n}\n}\n]\n},\n{\"known history of, or any evidence of active, interstitial lung disease or non-infectious pneumonitis requiring corticosteroid therapy\": true},\n{\"active serious infection requiring systemic therapy\": true},\n{\"major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study\": true},\n{\"history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate\": true},\n{\"known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\": true},\n{\n\"$and\": [\n{\"pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\": true},\n{\"prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\": true},\n{\"known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)\": true},\n{\"known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)\": true},\n{\"received a live vaccine within 30 days of planned start of study therapy\": true}\n]\n}\n]\n}"}